Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + cyclophosphamide + mitoxantrone liposomes + chidamide + prednisone-The Affiliated Hospital of Xuzhou Medical University-angioimmunoblastic T-cell lymphoma
- Development stage
- Phase 2
- Lead developer
- The Affiliated Hospital of Xuzhou Medical University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
This investigational combination therapy is being evaluated in a Phase 2 clinical trial for the treatment of newly diagnosed angioimmunoblastic T-cell lymphoma (AITL). The regimen consists of five distinct agents: tislelizumab, a humanized IgG4 monoclonal antibody targeting programmed cell death protein 1 (PD-1); cyclophosphamide, an alkylating chemotherapy agent; mitoxantrone liposomes, a liposomal formulation of the anthracenedione antineoplastic agent; chidamide, a selective histone deacetylase (HDAC) inhibitor; and prednisone, a synthetic corticosteroid. This multi-modal approach aims to improve outcomes in AITL by combining immune checkpoint blockade with cytotoxic chemotherapy and epigenetic modulation. The trial is sponsored by The Affiliated Hospital of Xuzhou Medical University.
- Other names
- Tislelizumab Combination for Newly Diagnosed AITL
02
Targets
DNATOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)HDAC1 (Histone Deacetylase 1)HDAC10 (Histone Deacetylase 10)HDAC2 (Histone deacetylase 2)HDAC3 (Histone Deacetylase 3)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on tislelizumab + cyclophosphamide + mitoxantrone liposomes + chidamide + prednisone-The Affiliated Hospital of Xuzhou Medical University-angioimmunoblastic T-cell lymphoma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + cyclophosphamide + mitoxantrone liposomes + chidamide + prednisone-The Affiliated Hospital of Xuzhou Medical University-angioimmunoblastic T-cell lymphoma.